Expertise in
17
conditions

Dr. Richard J. Bold

Surgical Oncology
AZ - Cancer
5777 E Mayo Blvd, 
Phoenix, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
17
conditions
AZ - Cancer
5777 E Mayo Blvd, 
Phoenix, AZ 

Overview

Richard Bold is a Surgical Oncologist practicing medicine in Phoenix, Arizona.

Dr. Bold is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Breast Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection.

He is actively involved in clinical research, co-authoring 110 peer reviewed articles and participating in 10 clinical trials.

Specialties

Surgical Oncology

Licenses

Surgery in CA

Hospital Affiliations

Mayo Clinic Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

AZ - Cancer
5777 E Mayo Blvd, Phoenix, AZ 85054

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Enrollment Status: Recruiting
Publish Date: April 23, 2026
Intervention Type: Drug, Other
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: June 25, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 9 Less Clinical Trials

110 Total Publications

Correction: Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer?
Correction: Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer?
Journal: Annals of surgical oncology
Published: August 04, 2026
Similar Doctors
Expertise in
7
conditions
Dr. Zhi V. Fong
Surgical Oncology
Expertise in
7
conditions
Dr. Zhi V. Fong
Surgical Oncology
Referral may be required

Mayo Clinic Hospital In Arizona

5777 E Mayo Blvd, 
Phoenix, AZ 
 (0.1 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Zhi Fong is a Surgical Oncologist practicing medicine in Phoenix, Arizona. Dr. Fong is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Gallbladder Disease, Pancreaticoduodenectomy, and Gallbladder Removal.

Expertise in
11
conditions
Dr. S Brenda-Moorthy
Surgical Oncology
Expertise in
11
conditions
Dr. S Brenda-Moorthy
Surgical Oncology
Referral may be required

Honorhealth Cancer Care-Comprehensive Breast Center Of Arizona-Deer Valley

19646 N 27th Ave Ste 407, 
Phoenix, AZ 
 (9.3 miles away)
602-786-0720
Languages Spoken:
English, Hindi, Spanish, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

S Brenda-Moorthy is a Surgical Oncologist practicing medicine in Phoenix, Arizona. Dr. Brenda-Moorthy is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Intraductal Papilloma, Angiosarcoma, and Lymphadenectomy. Dr. Brenda-Moorthy is currently accepting new patients.

Expertise in
22
conditions
Dr. Chinedu O. Mmeje
Surgical Oncology | Urology
Expertise in
22
conditions
Dr. Chinedu O. Mmeje
Surgical Oncology | Urology
Referral may be required
Before you request

Banner MD Anderson Cancer Center At Banner Gateway Medical Center

2946 East Banner Gateway Drive, 
Gilbert, AZ 
 (24.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I center my interests around advancing the care of patients with cancer. Dr. Mmeje is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Mmeje is board certified in American Board Of Urology. Dr. Mmeje is currently accepting new patients.

Frequently Asked Questions about Dr. Richard J. Bold

How do I make an appointment with Dr. Richard J. Bold?

You can book an appointment with Dr. Richard J. Bold by calling their office at 480-933-6836. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Richard J. Bold a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Richard J. Bold is classified as an Distinguished expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Richard J. Bold specialize in?

While Dr. Richard J. Bold is a Surgical Oncology, they have specific expertise in Pancreatic Cancer, Breast Cancer, and Pancreatectomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Richard J. Bold participate in research or clinical trials?

Yes. Dr. Richard J. Bold has published 110 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Richard J. Bold's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Richard J. Bold accept my insurance?

Dr. Richard J. Bold accepts most major insurance plans, including Humana and UnitedHealthcare. We recommend calling the office directly at 480-933-6836 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bold's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile